The Parties will take into account, as appropriate, international provisions, practices and guidelines for pharmaceutical products or medical devices, including those developed by the WHO, the OECD, the ICH, the GHTF and the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation Scheme (PIC/S). The Parties recognise that their full participation in those relevant international bodies will facilitate regulatory cooperation between them.
The Parties will consider the requests by either Party to accept conformity assessments [For the purposes of pharmaceutical products, conformity assessment means marketing authorisation of products, and the supervision/enforcement of manufacturers’ or importers’ compliance with technical standards/practices.] of that Party when performed in accordance with the Good Laboratory Practices and Good Manufacturing Practices of pharmaceutical products and medical devices and when both Parties’ corresponding practices are in accordance with international practices.
For the Working Group on Pharmaceutical Products and Medical Devices established pursuant to Article 15.3.1 (Working Groups), the Parties shall provide for adequate participation of officials of agencies or departments responsible for health care or other matters and regulations covered by this Annex.
The Working Group shall:
monitor and support the implementation of this Annex;
promote discussion and mutual understanding of issues related to this Annex; and
promote cooperation between the Parties to achieve the objectives set out in this Annex.
The Working Group shall meet at least once a year, unless agreed otherwise. The Working Group may also carry out its work by e-mail, teleconference or videoconference or any other appropriate means of communications.